A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Latest Information Update: 05 Dec 2025
At a glance
- Drugs BL-M24D1 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 05 Dec 2025 New trial record